A Dengue Vaccine

Anna P. Durbin

doi:10.1016/j.cell.2016.06.036

A Dengue Vaccine

Anna P. Durbin

Bloomberg School of Public Health

Research output: Contribution to journal › Short survey › peer-review

14 Scopus citations

Abstract

Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.

Original language	English (US)
Pages (from-to)	1
Number of pages	1
Journal	Cell
Volume	166
Issue number	1
DOIs	https://doi.org/10.1016/j.cell.2016.06.036
State	Published - 2016

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2016.06.036

Cite this

@article{9757fa772e4e43daa1a88367b36efc35,

title = "A Dengue Vaccine",

abstract = "Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.",

author = "Durbin, {Anna P.}",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2016",

doi = "10.1016/j.cell.2016.06.036",

language = "English (US)",

volume = "166",

pages = "1",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - A Dengue Vaccine

AU - Durbin, Anna P.

PY - 2016

Y1 - 2016

N2 - Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.

AB - Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.

UR - http://www.scopus.com/inward/record.url?scp=84982181886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982181886&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2016.06.036

DO - 10.1016/j.cell.2016.06.036

M3 - Short survey

C2 - 27368091

AN - SCOPUS:84982181886

SN - 0092-8674

VL - 166

SP - 1

JO - Cell

JF - Cell

IS - 1

ER -

A Dengue Vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this